# BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

Source: https://onco.cc/trials/nct07071844/  
OnCo record `nct07071844` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by GERCOR - Multidisciplinary Oncology Cooperative Group, not yet recruiting.

## Summary

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients is a phase 2, randomised interventional study registered as NCT07071844 by GERCOR - Multidisciplinary Oncology Cooperative Group, with a registry enrolment figure of 162 participants, started 2025-09 and due to reach its primary completion in 2028-12. Interventions recorded: Trifluridine/tipiracil; Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: The occurrence of at least one grade 3-4 neutropenia. Colorectal eligibility wording from the registry: "Histologically proven colorectal adenocarcinoma,". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: BETWEEN
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07071844
- Phase: 2
- Setting: BEvacizumab Plus Trifluridine/Tipiracil in a Bi-WEEkly Administration to Reduce Grade 3-4 Neutropenia in Patients With mCRC: A Prospective, Multicenter, Comparative, Randomized GERCOR G-124 BETWEEN Phase II Study
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Enrolled: 162

## Sources

- ClinicalTrials.gov NCT07071844: https://clinicaltrials.gov/study/NCT07071844

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- companies: [GERCOR](https://onco.cc/companies/gercor/), [Servier](https://onco.cc/companies/servier/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07071844.json